Yumanity Therapeutics Stock Forecast, Price & News

Yumanity Therapeutics (NASDAQ:YMTX) Frequently Asked Questions

Is Yumanity Therapeutics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Yumanity Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Yumanity Therapeutics stock.
View analyst ratings for Yumanity Therapeutics or view top-rated stocks.

Are investors shorting Yumanity Therapeutics?

Yumanity Therapeutics saw a decline in short interest in the month of December. As of December 15th, there was short interest totaling 61,200 shares, a decline of 61.4% from the November 30th total of 158,400 shares. Based on an average daily trading volume, of 175,700 shares, the short-interest ratio is currently 0.3 days. Currently, 0.9% of the company's shares are sold short.
View Yumanity Therapeutics' Short Interest.

When is Yumanity Therapeutics' next earnings date?

Yumanity Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 30th 2022.
View our earnings forecast for Yumanity Therapeutics.

How were Yumanity Therapeutics' earnings last quarter?

Yumanity Therapeutics, Inc. (NASDAQ:YMTX) posted its quarterly earnings results on Monday, November, 15th. The company reported ($0.97) EPS for the quarter, topping the Zacks' consensus estimate of ($1.13) by $0.16. The business earned $1.64 million during the quarter, compared to analyst estimates of $1.93 million. Yumanity Therapeutics had a negative net margin of 605.00% and a negative trailing twelve-month return on equity of 147.18%.
View Yumanity Therapeutics' earnings history.

What price target have analysts set for YMTX?

2 equities research analysts have issued 1-year price objectives for Yumanity Therapeutics' shares. Their forecasts range from $35.00 to $39.00. On average, they expect Yumanity Therapeutics' stock price to reach $37.00 in the next twelve months. This suggests a possible upside of 1,933.0% from the stock's current price.
View analysts' price targets for Yumanity Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Yumanity Therapeutics' key executives?

Yumanity Therapeutics' management team includes the following people:

• Richard Peters, President, CEO, Secretary, Treasurer & Director
• Michael D. Wyzga, Chief Financial Officer & Senior Vice President
• Ajay Verma, Executive VP, Head-Research & Development
• Brigitte Robertson, Chief Medical Officer
• Daniel Tardiff, Research Head

Who are some of Yumanity Therapeutics' key competitors?

Some companies that are related to Yumanity Therapeutics include Akari Therapeutics (AKTX), Biofrontera (BFRA), 4D pharma (LBPS), Millendo Therapeutics (MLND), Orphazyme A/S (ORPH), HCW Biologics (HCWB), Emmaus Life Sciences (EMMA), Galera Therapeutics (GRTX), Capricor Therapeutics (CAPR), Osmotica Pharmaceuticals (OSMT), vTv Therapeutics (VTVT), NexImmune (NEXI), Heat Biologics (HTBX), Evofem Biosciences (EVFM) and Lantern Pharma (LTRN).
View all of YMTX's competitors.

What is Yumanity Therapeutics' stock symbol?

Yumanity Therapeutics trades on the NASDAQ under the ticker symbol "YMTX."

How do I buy shares of Yumanity Therapeutics?

Shares of YMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Yumanity Therapeutics' stock price today?

One share of YMTX stock can currently be purchased for approximately $1.82.

How much money does Yumanity Therapeutics make?

Yumanity Therapeutics has a market capitalization of $18.76 million and generates $6.90 million in revenue each year.

How many employees does Yumanity Therapeutics have?

Yumanity Therapeutics employs 45 workers across the globe.

What is Yumanity Therapeutics' official website?

The official website for Yumanity Therapeutics is www.yumanity.com.

Where are Yumanity Therapeutics' headquarters?

Yumanity Therapeutics is headquartered at 40 GUEST STREET SUITE 4410, BOSTON MA, 02135.

How can I contact Yumanity Therapeutics?

Yumanity Therapeutics' mailing address is 40 GUEST STREET SUITE 4410, BOSTON MA, 02135. The company can be reached via phone at (617) 409-5300 or via email at [email protected].